Robert Finberg
Infectious Disease · Worcester, MANPI 1790767580
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,775 of the $1,795 with a category attached, or 98.9%. Eisai Inc. accounts for 71.0% of it on its own, with 2 other manufacturers making up the rest.
Across 3 payments — averaging $598.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$1K
- Eli Lilly$500
- Pfizer$20
Across 76 payments — averaging $23,491 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.6M
- Eli Lilly$159K
- PTC Therapeutics, Inc.$44K
- Emergent Biosolutions Inc.$18K
- Gilead$1K
What the payments were for
- Consulting fees$1,77599%
- Gifts$201%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 1 | $1,275 |
| Eli Lilly | 1 | $500 |
| Pfizer | 1 | $20 |
How this compares
$1,795 in reported general payments places this provider in the 75th percentile of 368 infectious disease providers in Massachusetts.
Other infectious disease in Worcester
- Thomas GreenoughWorcester$83K
- Joyce FingerothWorcester$59K
- Sanjay RamWorcester$34K
- Laura GibsonWorcester$14K
- Mireya WessolosskyWorcester$8K
- Richard EllisonWorcester$4K
- Yoav GolanBoston$1.1M
- Claudia MartorellSpringfield$990K
- Nesli BasgozBoston$901K
- Todd EllerinBoston$843K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.